



COPY OF PAPERS
ORIGINALLY FILED

#12
9-23-02
NW

S/N 09/590,002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lawrence L. Kunz et al.	Examiner:	Samuel Barts
Serial No.:	09/590,002	Group Art Unit:	1621
Filed:	June 8, 2000	Docket:	295.007US4
Title:	THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS		

RESPONSE UNDER 37 C.F.R. § 1.111

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

SEP 13 2002

TECH CENTER 1600/2900

Sir:

In response to the Office Action mailed on June 5, 2002, please consider the following remarks.

On Form PTO-326 included with the Office Action, the Examiner indicated that the pending claims are claims 26-100. However, claims 101-104 were added in the Supplemental Preliminary Amendment and Response to Restriction Requirement filed on June 28, 2001 in the above-identified application. Hence, it is respectfully submitted that the pending claims are claims 26-104.

The Examiner rejected claims 26-104 under the judicially created doctrine of obviousness-type double patenting over claims 1-18 of U.S. Patent No. 5,811,447. This rejection is respectfully traversed.

The claims in the present application are directed to a method for treating a traumatized mammalian vessel, comprising, following the surgical excision or isolation of a graft vessel, exposing the graft vessel to a therapeutic agent in an amount effective to decrease or prevent diminution in the luminal area of the graft vessel following engraftment of the graft vessel (claims 26-31, 67 and 69). The claims in the present application are also directed to a method for maintaining vessel luminal area, comprising inserting into a mammalian vessel an intravascular stent comprising an amount of a cytoskeletal inhibitor effective to reduce stenosis or restenosis upon placement of the stent (claims 32-42 and 67); a method for maintaining vessel luminal area, comprising inserting into a mammalian vessel an intravascular stent comprising an amount of a cytochalasin or an analog thereof effective to inhibit or reduce stenosis or restenosis upon placement of the stent (claims 70-76 and 81-83); a method for maintaining vessel luminal area, comprising inserting into a mammalian vessel an intravascular stent which comprises a matrix and a coating on said matrix, wherein the coating and the matrix together comprise an amount of